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Previewswith constitutive activation of the NF-kB
pathway demonstrated B cell and plasma
cell hyperplasia, with frequent presence
of serum monoclonal M-spikes. Mice
with Blimp1 inactivation demonstrated
presence of CD138, IRF4+, and BCL6
monoclonal large B cell tumors with highly
somatically mutated immunoglobulin
genes, consistent with an ABC-like
human DLBCL. Similarly, mice with
combined constitutive activation of NF-
kB and BLIMP1 inactivation who showed
shorter survival also developed B cell
lymphomas similar to human ABC-like
DLBCL.
These two manuscripts explicitly
demonstrate that BLIMP1 is a bona-fide
tumor suppressor gene involved in the
pathogenesis of ABC-like DLBCL. They
also prove that blocking differentiation is
an important step in the pathogenesis of
the ABC-like subtype. However, they still
do not resolve the enigma of the nature
of the precursor cell in this subtype.
Furthermore, the study by Calado et al.also clearly demonstrates the synergy in
oncogenesis between lesions that block
differentiation (BLIMP1) and promote
proliferation/survival (NF-kB). However,
the low DLBCL penetrance and long
latency in these mice suggest that addi-
tional transformation events are most
probably required for development of the
ABC-like tumors. A search in mice tumors
for mutations affecting proteins control-
ling activation of the NF-kB (e.g., A20),
commonly found in human ABC-like
DLBCL, was negative. Identifying addi-
tional pathophysiologic mechanisms
contributing to the pathogenesis of
DLBCL and generation of drugs specifi-
cally targeting the ‘‘culprits’’ will be next
important steps.REFERENCES
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In this issue ofCancer Cell, Rui et al. identify JAK2 and JMJDC2 as two contiguous, coamplified oncogenes in
primary mediastinal B cell and Hodgkin lymphoma. Together, JAK2 and JMJD2C induce major changes in
chromatin structure and gene expression. Targeting these proteins with small molecules represents a new
avenue for therapy.The classification of lymphoma hasmoved
beyond morphology to ever more refined
molecular subtypes, with distinct thera-
peutic implications. Gene expression
profiling led to the classification of diffuse
large B cell lymphoma (DLBCL) into acti-
vated B cell, germinal center B cell, and
primary mediastinal B cell lymphoma
(PMBL) subtypes (Dave et al., 2006).Profiling also showed that PMBL and
Hodgkin’s lymphoma (HL) could be
grouped together (Rosenwald et al.,
2003). Genome-wide copy number anal-
ysis coupled with expression profiling rein-
forced the view that these subtypes are
pathogenetically distinct diseases (Lenz
et al., 2008). PMBL and HL, in particular,
frequently display amplification of chromo-somes 2p and 9p. Amplification of REL at
2p14-16, which encodes c-Rel (a subunit
of NF-kB), induces the constitutive activa-
tion of that antiapoptotic pathway.
JAK2 and JMJDC2 were among the
genes previously suspected but not
proved to have pathogenic roles within
the 9p23-24 amplicon. To define the
critical genes within the 9p amplicon inecember 14, 2010 ª2010 Elsevier Inc. 539
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PreviewsPML and HL, Rui et al. (2010) took a
functional approach, creating a library of
shRNA molecules targeting each of the
overexpressed putative oncogenes within
the amplicon. Using a robust screen, they
showed that depletion of JAK2 and
JMJD2C, as well as the uncharacterized
gene RANBP6, was toxic for PMBL and
HL but not other lymphoma cells (Rui
et al., 2010).
JAK2 is a tyrosine kinase that dockswith
cytokine receptors and regulates cell
proliferation, differentiation, apoptosis,
and cell migration in part by phosphoryla-
tion of STAT transcription factors. JAK2
gained notoriety because of the presence
of constitutive activating mutations of the
protein in polycythemia vera and other
myeloproliferative neoplasms (MPN).
However, the oncogenic effect of JAK2 in
PMBL and HL is due to its overexpression,
which is associatedwith constitutive phos-
phorylation and activation of the kinase. In
PMBL, JAK2 hyperactivity was associated
with STAT6 activation, IL13 secretion, IL13
receptor expression, and a feed-forward
autocrine loop to further support cell prolif-
eration (Rui et al., 2010). Thus, antibodies
directed to IL13 represent a way to inter-
fere with the oncogenic program of these
cells. Furthermore, PMBL and HL lines
were sensitive to JAK2 inhibitors, suggest-
ing that these drugs, currently in clinical
trial for MPN, might play a role in the treat-
ment of these specific forms of lymphoma
(Rui et al., 2010).
Rui et al. (2010) further show that JAK2
cooperated with both JMJD2C and
RANBP6 to support lymphoma growth,
with JAK2 knockdown or inhibition leading
to cell death and JMJDC2 and RANBP6
depletion to cell cycle arrest. JMJD2C
was originally identified as GASC1,
a gene amplified in gastric carcinoma,
and can be rearranged with the immuno-
globulin locus in mucosa associated
lymphoma tissue (MALT) lymphoma.
JMJDC2 is an iron and 2-oxoglutarate-
dependent dioxygenase that catalyzes de-
methylation of histone 3 on lysine 9 (H3K9)
(Cloos et al., 2006). Depletion of JMJD2C
from cancer cells as well as murine
embryonic stem cells decreased overall
trimethylated H3K9 (H3K9me3) levels and
cell proliferation and c-MYCwas identified
as one target potentially responsible for
this effect (Wang et al., 2010). JAK2 and
JMJDC2 converged on a common chro-
matin mechanism in PMBL and HL. The540 Cancer Cell 18, December 14, 2010 ª20laboratories of Kouzarides and Green first
showed that a fraction of JAK2 enters the
nucleus where it phosphorylates the
histone H3 on tyrosine 41 (H3Y41),
precluding the binding of chromo-shadow
domain of heterochromatin protein 1 (HP1)
to histone tails (Dawson et al., 2009). HP1
normally facilitates heterochromatin
formation by binding to H3K9me3 through
its chromo domain and can cause hetero-
chromatin spreading by the attraction of
H3K9 methyl transferases G9s, ESET,
SETDB1, and Su(Var)39. Increased
JMJD2C activity would break this cycle
by removing the key H3K9me3 mark.
Accordingly, Rui et al. (2010) showed that
inhibition or depletion of JAK2 and deple-
tion of JMJD2C in PMBL cells led to
a global increase in H3K9me3 levels and
foci of HP1 staining.
Rui et al. (2010) demonstrated that JAK2
inhibition and JMJD2C knockdown
decreased expression of c-MYC and
c-MYC target genes and increased the
level of H3K9 trimethylation at the
c-MYC promoter (Rui et al., 2010). There
was a surprisingly modest effect of JAK2
inhibition on genes containing STAT
binding sites, suggesting that direct chro-
matin phosphorylation by JAK2 and not
activation of STATs was the predominant
activity of overexpressed JAK2 in PMBL.
Supporting this, genome-wide mapping
of H3Y41 phosphorylated chromatin iden-
tified >2000 genes potentially directly
bound and activated by JAK2, including
JAK2 itself, JMJD2C, and c-MYC. Given
the fundamental role of c-MYC in cancer
and embryonic stem cell self-renewal, it is
perhaps not surprising that its depletion in-
hibited the growth of all PMBL and HL cell
lines tested. However, a drive to express
c-MYC cannot fully explain the oncogenic
action of JMJD2C and JAK since c-MYC
overexpression could not rescue the effect
of JAK2 or JMJDC2 knockdown (Rui et al.,
2010). The identities of genes bound and
regulated by JMJD2C and/or JAK2 critical
to PMBL and HL remain to be determined.
Regardless, the autoregulation of JAK2
emphasizes the importance of targeting
thisprotein tobreakpositive reinforcement
of aberrant signaling, gene expression,
proliferation, and self-renewal.
RANBP6was the third gene identified in
the work of Rui et al. (2010), but its mode
of action remains obscure. RANBP6 is
over 80% similar to importin 5 (RANBP5),
a RAN GTP binding protein implicated in10 Elsevier Inc.recognition of nuclear localization signals
and directional transport of proteins into
the nucleus. Overexpression of other im-
portins was associated with an adverse
prognosis in cancer (Chahine and Pierce,
2009), and a truncated form of an importin
identified in a breast cancer cell line
blocked proper nuclear import of p53. It
is thus possible that RANBP6 overexpres-
sion may lead to aberrant nuclear locali-
zation of gene regulators, contributing to
malignancy. Whether RANBP6 affects
chromatin or gene expression pathways
similar to or distinct from those affected
by JAK2 and JMJDC2 remains to be
determined.
Global epigenetic changes represent
an emerging, recurrent theme in cancer.
A wide variety of cancers were shown to
be deficient in H4K20me3 as well as
DNA methylation, although the reason
for this remains unclear. Global decreases
of H3K27 methylation were associated
with a poor prognosis in severalmalignan-
cies. In many cases, epigenetic changes
can be directly linked to cancer genetics.
For example, loss of theH3K27me3modi-
fication was associated with inactivating
mutations of EZH2 inmyeloidmalignancy,
while increased H3K27me3 was associ-
ated with a gain of function mutation of
EZH2 in lymphoma (Morin et al., 2010;
Sneeringer et al., 2010). Myeloma associ-
ated with rearrangement of the WHSC1/
MMSET gene displays increased H3K36
methylation and decreased H3K27 meth-
ylation, and mutation of SETD2 in renal
cell carcinoma was associated with loss
of H3K36 methylation. Furthermore,
mutations in a DNA methyltransferase
DNAMT3a in AML, presumed to be inacti-
vating or dominant negative in nature,
were associated with DNA methylation
changes, and inactivating mutation of
TET2 is associated with global changes
in DNA hydroxymethylation and methyla-
tion. To this list of disorders associated
with widespread chromatin aberration
we can add PMBL/HL and JAK2-associ-
ated MPN. In the case of the 9p amplicon
of PMBL/HL, aberrant expression of two
epigenetic modulators at the same time
appeared to cooperate in carcinogenesis.
Changes in expression and activity of
enzymes regulating chromatin structure
upset the normal balance of gene regula-
tion. Which genes change in response to
a global insult and whether these disor-
ders all converge on common oncogene
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Previewsnetworks, such as that of MYC, remains
to be determined. While Rui et al. (2010)
showed that JAK2 inhibitors affect chro-
matin in PMBL and abrogate an onco-
genic program, whether these agents
affect MPN in the same manner remains
to be determined. On the horizon
are histone demethylase inhibitors. A
JMJDC2 inhibitor was recently identified
(Hamada et al., 2010), and it will be critical
to test the activity of such agents in
PMBL, HL, MPN, and other tumors that
harbor the 9p23-24 amplicon.
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Tvorogov et al. (2010) describe in this issue of Cancer Cell an antibody that inhibits homodimerization of
vascular endothelial growth factor receptor-3 (VEGFR-3) and its heterodimerization with VEGFR-2, but not
ligand binding. The work provides mechanistic insights into receptor dimerization and an approach to
suppress both angiogenesis and lymphangiogenesis.More than 800,000 cancer patients world-
wide are currently being treated with
angiogenesis inhibitors. Treatment with
the monoclonal antibody bevacizumab to
block vascular endothelial growth factor
(VEGF), a cytokine that promotes blood
vessel growth, delays progression, and
prolongs survival in some cancers (Bagri
et al., 2010). Other macromolecular thera-
peutics that block VEGF signaling, in-
cluding ramucirumab, an antibody that
targets VEGF receptor-2 (VEGFR-2), and
aflibercept, a chimeric decoy receptor
that binds VEGF, are in advanced clinical
trials (http://www.clinicaltrials.gov). These
agents are selective, are well tolerated,and generally have only modest side
effects restricted to consequences of
inhibiting VEGF in normal organs.
However, selective VEGF blockers are
efficacious in many cancers only when
administered in combination with chemo-
therapy, and tumors can progress while on
therapy. The slowing of tumor growth after
inhibition of VEGF signaling can be accom-
panied by increased invasiveness and
metastasis in some preclinical models
(Paez-Ribes et al., 2009). The mechanisms
of dependence on chemotherapy, progres-
sion during treatment, and exaggerated
aggressivenessareunclear,butmoreeffica-
ciousapproachesare actively being sought.Receptor-blocking antibodies that tar-
get the ligand-binding site of receptors
compete with the ligand. This type of
inhibitor has the potential limitation of
being less efficient at high ligand concen-
trations, when the ligand out-competes
the inhibitor. Because delivery of anti-
bodies to tumors is hampered by ineffi-
cient blood vessels, erratic blood flow,
and high intratumoral pressure, inhibitors
may not reach their molecular targets in
sufficient amount and uniformity to be fully
efficacious. In addition, other mecha-
nisms contribute to the limitations of
efficacy of angiogenesis inhibitors.
Factors other than VEGF can promoteecember 14, 2010 ª2010 Elsevier Inc. 541
